Therapeutic effect of epigallocatechin gallate on hyperlipidemic fatty liver in rats

Chinese Pharmacological Bulletin

Volumn 25, Issue 4, 2009, Pages

  Ge, Bin ^a,b   Xie, Mei Lin ^a,b   Gu, Zhen Lun ^a,b   Qian, Pei Gang ^a,b   Zhou, Wen Xuan ^b   Guo, Ci Yi ^b  

^a SOOCHOW UNIVERSITY   (China)

^b Suzhou Institute of Chinese Materia Medica   (China)

Author keywords

Cholesterol; Epigallocatechin gallate (EGCG); Hyperlipidemic fatty liver; Pharmacodynamics; Triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIGALLOCATECHIN GALLATE; FATTY ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ELECTRON MICROSCOPY; FATTY LIVER; HISTOPATHOLOGY; HYPERLIPIDEMIA; LIPID STORAGE; LIVER WEIGHT; NONHUMAN; RAT; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 68549117082     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Angulo P. Non-alcoholic fatty liver disease[J]. Rev Gastroenterol Mex, 2005, 70(3): 52-56
2. Farrell G C, Larter C Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis[J]. Hepatology, 2006, 43(2): 99-112.
3. Ding Y X, Tian J Y, Ma J B. Protective effects of green tea polyphenol(-) epigallocatechin gallate on cultured cortical neurons in mice[J]. Chin Pharmacol Bull, 2008, 24(1): 105-108
4. Yang X, Li C R, Zhu Z H, et al. Protective effect of EGCG on experimental diabetic nephropathy in rats[J]. Chin Pharmacol Bull, 2006, 22(1): 84-88
5. Zhou X R, Gong Z J, Yuan G J, et al. Effects of tea polyphenols on alcoholic liver injury in rats[J]. World Chin J Digestol, 2006, 14(1): 50-56
6. Bose M, Lambert J D, Ju J, et al. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice[J]. J Nutr, 2008, 138(9): 1677-1683
7. Moon H S, Lee H G, Choi Y J, et al. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity[J]. Chem Biol Interact, 2007, 167(2): 85-98.
8. Sheng R, Gu Z L, Xie M L, et al. EGCG inhibition against collagen accumulation and cell proliferation in cardiac hypertrophy[J]. Chin Pharmacol Bull, 2006, 22(9): 1095-1099 (Pubitemid 44912568)
9. Zhang Y, Xie M L, Zhu L J, et al. Therapeutic effect of osthole on hyperlipidemic fatty liver in rats[J]. Acta Pharm Sin, 2007, 28(3): 398-403.
10. Zou Y, Li J, Lu C, et al. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis[J]. Life Sci, 2006, 79(11): 1100-7. (Pubitemid 44102717)
11. Lieber C S, Leo M A, Mak K M, et al. Model of nonalcoholic steatohepatitis[J]. Am J Clin Nutr, 2004, 79(3): 502-509
12. Song F, Xie M L, Zhu L J, et al. Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals[J]. World J Gastroenterol, 2006, 12(27): 4359-4363 (Pubitemid 44194529)
13. Rector R S, Thyfault J P, Wei Y, et al. Non-alcoholic fatty liver disease and the metabolic syndrome: An update[J]. World J Gastroenterol, 2008, 14(2): 185-192 (Pubitemid 351314297)